Granisetron Transdermal System

2009 ◽  
Vol 44 (4) ◽  
pp. 332-339 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Proton Pump ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Fibrinogen Concentrate ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2009 monograph topics are dexlansoprazole, milnacipran, oxybutynin chloride 10% gel, fibrinogen concentrate (human), and ecallantide injection. The DUE is on proton pump inhibitors.

Clevidipine Butyrate Injectable Emulsion

2008 ◽  
Vol 43 (11) ◽  
pp. 903-912 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2008 monograph topics are on romiplostim, rivaroxaban, golimumab, dronedarone, and degarelix. The DUE is on romiplostim.

Febuxostat

2009 ◽  
Vol 44 (8) ◽  
pp. 688-699
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation ◽  
Ophthalmic Suspension

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2009 monograph topics are tolvaptan, besifloxacin ophthalmic suspension 0.6%, tadalafil, bromocriptine mesylate, and acetaminophen intravenous. The DUE is on tolvaptan.

Alvimopan

2008 ◽  
Vol 43 (10) ◽  
pp. 819-829
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Tenofovir Disoproxil Fumarate ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and are also available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The FIX., call The Formulary at 800-322-4349. The October 2008 monograph topics are on clevidipine butyrate injectable emulsion, tetrabenazine, tenofovir disoproxil fumarate tablets, ferumoxytol, and saxagliptin. The DUE is on clevidipine butyrate injectable emulsion.

Tigecycline

2005 ◽  
Vol 40 (10) ◽  
pp. 897-907 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2005 monograph topics are ramelteon, lidocaine/tetracaine patch, dapsone gel, altrasentan, and deferasirox. The DUE is on ramelteon.

Golimumab

2009 ◽  
Vol 44 (10) ◽  
pp. 894-907 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2009 monograph topics are fentanyl buccal soluble film, laromustine, paliperidone injection, saxagliptin, and trepostinil inhalation. The DUE is on fentanyl soluble film.

Fidaxomicin

2011 ◽  
Vol 46 (11) ◽  
pp. 884-890
Author(s):  
J. Cada Dennis ◽  
L. Levien Terri ◽  
E. Baker Danial
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
On Line ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The November 2011 monograph topics are on indacaterol, brentuximub vedotin, icatibant injection, aflibercept, and centruroides (Scorpion) immune F(ab′)2. The DUE/MUE is on indacaterol.

Lanthanum Carbonate

2005 ◽  
Vol 40 (3) ◽  
pp. 250-261
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Pharmacy And Therapeutics Committee ◽  
Cd Rom ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The March 2005 monograph topics are ziconotide, eszopiclone, palifermin, paclitaxel, and darifenacin. The DUE is on eszopiclone.

Antithrombin (Recombinant)

2009 ◽  
Vol 44 (9) ◽  
pp. 785-793 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2009 monograph topics are dronedarone, prasugrel, ferumoxytol injection, canakinumab injection, and ibuprofen injection. The DUE is on dronedarone.

Rufinamide

2009 ◽  
Vol 44 (5) ◽  
pp. 412-422 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Prostatic Hyperplasia ◽  
Bulletin Board ◽  
Phase 3 ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The May 2009 monograph topics are febuxostat, antithrombin (recombinant), calcitriol ointment, trabectedin, and tesamorelin. The class review is on drugs used in the therapy of benign prostatic hyperplasia, and the DUE is on febuxostat.

Ustekinumab

2010 ◽  
Vol 45 (4) ◽  
pp. 320-331
Author(s):  
Dennis J. Cada ◽  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Drug Utilization ◽  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Bulletin Board ◽  
Collagenase Clostridium Histolyticum ◽  
Phase 3 ◽  
Clostridium Histolyticum ◽  
Target Drug ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing inservices. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent in print and are also available online. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2010 monograph topics are on liraglutide, dalfampridine, collagenase clostridium histolyticum for injection, roflumilast, and belimumab. The DUE is on liraglutide.

Sign in / Sign up

Export Citation Format

Share Document